These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

400 related items for PubMed ID: 11966741

  • 1. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P, Isidro L, Leal-Cerro A, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [Abstract] [Full Text] [Related]

  • 2. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
    Leal-Cerro A, Soto A, Martínez MA, Alvarez P, Isidro L, Casanueva FF, Dieguez C, Cordido F.
    Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone (GH) rebound rise following somatostatin infusion withdrawal: studies in dogs with the use of GH-releasing hormone and a GH-releasing peptide.
    Rigamonti AE, Cavallera G, Bonomo S, Deghenghi R, Locatelli V, Cella SG, Müller EE.
    Eur J Endocrinol; 2001 Nov; 145(5):635-44. PubMed ID: 11720883
    [Abstract] [Full Text] [Related]

  • 4. Somatostatin infusion withdrawal: studies in the acute and recovery phase of anorexia nervosa, and in obesity.
    Pincelli AI, Rigamonti AE, Scacchi M, Cella SG, Cappa M, Cavagnini F, Müller EE.
    Eur J Endocrinol; 2003 Feb; 148(2):237-43. PubMed ID: 12590644
    [Abstract] [Full Text] [Related]

  • 5. GH and cortisol rebound rise during and following a somatostatin infusion: studies in dogs with the use of a GH-releasing peptide.
    Rigamonti AE, Bonomo SM, Cella SG, Müller EE.
    J Endocrinol; 2002 Sep; 174(3):387-94. PubMed ID: 12208658
    [Abstract] [Full Text] [Related]

  • 6. Marked GH secretion after ghrelin alone or combined with GH-releasing hormone (GHRH) in obese patients.
    Alvarez-Castro P, Isidro ML, Garcia-Buela J, Leal-Cerro A, Broglio F, Tassone F, Ghigo E, Dieguez C, Casanueva FF, Cordido F.
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):250-5. PubMed ID: 15272922
    [Abstract] [Full Text] [Related]

  • 7. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F, Fernandez T, Martinez T, Peñalva A, Peinó R, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [Abstract] [Full Text] [Related]

  • 8. Comparison between insulin tolerance test, growth hormone (GH)-releasing hormone (GHRH), GHRH plus acipimox and GHRH plus GH-releasing peptide-6 for the diagnosis of adult GH deficiency in normal subjects, obese and hypopituitary patients.
    Cordido F, Alvarez-Castro P, Isidro ML, Casanueva FF, Dieguez C.
    Eur J Endocrinol; 2003 Aug; 149(2):117-22. PubMed ID: 12887288
    [Abstract] [Full Text] [Related]

  • 9. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
    Massoud AF, Hindmarsh PC, Brook CG.
    Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
    [Abstract] [Full Text] [Related]

  • 10. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M, Bossoni S, Alí A, Doga M, Reimondo G, Milani G, Peretti P, Manelli F, Angeli A, Giustina A.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [Abstract] [Full Text] [Related]

  • 11. Contribution of growth hormone-releasing hormone and somatostatin to decreased growth hormone secretion in elderly men.
    Soule SG, Macfarlane P, Levitt NS, Millar RP.
    S Afr Med J; 2001 Mar; 91(3):254-60. PubMed ID: 11291426
    [Abstract] [Full Text] [Related]

  • 12. Elevated insulin levels contribute to the reduced growth hormone (GH) response to GH-releasing hormone in obese subjects.
    Lanzi R, Luzi L, Caumo A, Andreotti AC, Manzoni MF, Malighetti ME, Sereni LP, Pontiroli AE.
    Metabolism; 1999 Sep; 48(9):1152-6. PubMed ID: 10484056
    [Abstract] [Full Text] [Related]

  • 13. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

  • 14. The GH-releasing effect of ghrelin, a natural GH secretagogue, is only blunted by the infusion of exogenous somatostatin in humans.
    Di Vito L, Broglio F, Benso A, Gottero C, Prodam F, Papotti M, Muccioli G, Dieguez C, Casanueva FF, Deghenghi R, Ghigo E, Arvat E.
    Clin Endocrinol (Oxf); 2002 May; 56(5):643-8. PubMed ID: 12030916
    [Abstract] [Full Text] [Related]

  • 15. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L, Maccario M, Lanfranco F, Ramunni J, Di Vito L, Grottoli S, Muller EE, Ghigo E, Arvat E.
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [Abstract] [Full Text] [Related]

  • 16. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M, Maccario M, Grottoli S, Oleandri SE, Boffano GM, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
    [Abstract] [Full Text] [Related]

  • 17. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ, Nam SY, Kim KR, Lee HC, Cho JH, Nam MS, Song YD, Lim SK, Huh KB.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [Abstract] [Full Text] [Related]

  • 18. Abuse of recombinant human growth hormone: studies in two different dog models.
    Rigamonti AE, Scanniffio D, Bonomo SM, Cella SG, Sartorio A, Müller EE.
    Neuroendocrinology; 2004 Aug; 79(5):237-46. PubMed ID: 15218318
    [Abstract] [Full Text] [Related]

  • 19. Effect of somatostatin infusion on the somatotrope responsiveness to growth hormone-releasing hormone in patients with anorexia nervosa.
    Gianotti L, Rolla M, Arvat E, Belliti D, Valetto MR, Ferdeghini M, Ghigo E, Müller EE.
    Biol Psychiatry; 1999 Feb 01; 45(3):334-9. PubMed ID: 10023511
    [Abstract] [Full Text] [Related]

  • 20. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S, Procopio M, Maccario M, Zini M, Oleandri SE, Tassone F, Valcavi R, Ghigo E.
    J Clin Endocrinol Metab; 1997 Jul 01; 82(7):2261-5. PubMed ID: 9215304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.